AU Patent

AU2019350581B2 — Methods of treatment of cancer comprising Cdc7 inhibitors

Assigned to Carna Biosciences Inc · Expires 2025-07-10 · 1y expired

What this patent protects

Herein disclosed are methods of treatment administering SRA141 as a monotherapy or in a combination therapy useful for inhibiting the growth of tumors such as those in patients with cancer.

USPTO Abstract

Herein disclosed are methods of treatment administering SRA141 as a monotherapy or in a combination therapy useful for inhibiting the growth of tumors such as those in patients with cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019350581B2
Jurisdiction
AU
Classification
—
Expires
2025-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Carna Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.